Skip to content
OpenCapital
Get started

Neuropace, Inc. NPCE Operating Lease Liability Payments - 2024 (Lessee)

Operating Lease Liability Payments - 2024 (Lessee) at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s operating lease liability payments - 2024 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s operating lease liability payments - 2024 (lessee)?
Neuropace, Inc. (NPCE) reported operating lease liability payments - 2024 (lessee) of $3.22M in Q1 2026.
How has Neuropace, Inc.'s operating lease liability payments - 2024 (lessee) changed year-over-year?
Neuropace, Inc.'s operating lease liability payments - 2024 (lessee) increased by 3.0% year-over-year, from $3.12M to $3.22M.
What is the long-term trend for Neuropace, Inc.'s operating lease liability payments - 2024 (lessee)?
Over 3 years (2022 to 2025), Neuropace, Inc.'s operating lease liability payments - 2024 (lessee) has grown at a 3.0% compound annual growth rate (CAGR), from $2.86M to $3.12M.